Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Crebinostat: a novel cognitive enhancer that inhibits histone deacetylase activity and modulates chromatin-mediated neuroplasticity.

Fass DM, Reis SA, Ghosh B, Hennig KM, Joseph NF, Zhao WN, Nieland TJ, Guan JS, Kuhnle CE, Tang W, Barker DD, Mazitschek R, Schreiber SL, Tsai LH, Haggarty SJ.

Neuropharmacology. 2013 Jan;64:81-96. doi: 10.1016/j.neuropharm.2012.06.043. Epub 2012 Jul 4.

2.

The potential of HDAC inhibitors as cognitive enhancers.

Gräff J, Tsai LH.

Annu Rev Pharmacol Toxicol. 2013;53:311-30. doi: 10.1146/annurev-pharmtox-011112-140216. Review.

PMID:
23294310
3.

A role for histone deacetylases in the cellular and behavioral mechanisms underlying learning and memory.

Mahgoub M, Monteggia LM.

Learn Mem. 2014 Sep 16;21(10):564-8. doi: 10.1101/lm.036012.114. Print 2014 Oct. Review.

4.

Epigenetic landscape of amphetamine and methamphetamine addiction in rodents.

Godino A, Jayanthi S, Cadet JL.

Epigenetics. 2015;10(7):574-80. doi: 10.1080/15592294.2015.1055441. Review.

5.

Epigenetic histone acetylation and deacetylation mechanisms in experimental models of neurodegenerative disorders.

Konsoula Z, Barile FA.

J Pharmacol Toxicol Methods. 2012 Nov-Dec;66(3):215-20. doi: 10.1016/j.vascn.2012.08.001. Epub 2012 Aug 10. Review.

PMID:
22902970
6.

Non-sirtuin histone deacetylases in the control of cardiac aging.

Ferguson BS, McKinsey TA.

J Mol Cell Cardiol. 2015 Jun;83:14-20. doi: 10.1016/j.yjmcc.2015.03.010. Epub 2015 Mar 16. Review.

7.

Histone acetylation: molecular mnemonics on the chromatin.

Gräff J, Tsai LH.

Nat Rev Neurosci. 2013 Feb;14(2):97-111. doi: 10.1038/nrn3427. Epub 2013 Jan 17. Review.

PMID:
23324667
8.

Probing the role of HDACs and mechanisms of chromatin-mediated neuroplasticity.

Haggarty SJ, Tsai LH.

Neurobiol Learn Mem. 2011 Jul;96(1):41-52. doi: 10.1016/j.nlm.2011.04.009. Epub 2011 Apr 27. Review.

9.

Epigenetic regulation of memory by acetylation and methylation of chromatin: implications in neurological disorders, aging, and addiction.

Sen N.

Neuromolecular Med. 2015 Jun;17(2):97-110. doi: 10.1007/s12017-014-8306-x. Epub 2014 Apr 29. Review.

PMID:
24777294
10.

Histone deacetylase 3 (HDAC 3) as emerging drug target in NF-κB-mediated inflammation.

Leus NG, Zwinderman MR, Dekker FJ.

Curr Opin Chem Biol. 2016 Aug;33:160-8. doi: 10.1016/j.cbpa.2016.06.019. Epub 2016 Jun 29. Review.

11.

The acetyl code in rheumatoid arthritis and other rheumatic diseases.

Angiolilli C, Baeten DL, Radstake TR, Reedquist KA.

Epigenomics. 2017 Apr;9(4):447-461. doi: 10.2217/epi-2016-0136. Epub 2017 Jan 19. Review.

PMID:
28102705
12.

Inside HDACs with more selective HDAC inhibitors.

Roche J, Bertrand P.

Eur J Med Chem. 2016 Oct 4;121:451-483. doi: 10.1016/j.ejmech.2016.05.047. Epub 2016 May 25. Review.

PMID:
27318122
13.

The NMDA receptor as a target for cognitive enhancement.

Collingridge GL, Volianskis A, Bannister N, France G, Hanna L, Mercier M, Tidball P, Fang G, Irvine MW, Costa BM, Monaghan DT, Bortolotto ZA, Molnár E, Lodge D, Jane DE.

Neuropharmacology. 2013 Jan;64:13-26. doi: 10.1016/j.neuropharm.2012.06.051. Epub 2012 Jul 11. Review.

14.

Role of ERK signaling in activity-dependent modifications of histone proteins.

Ciccarelli A, Giustetto M.

Neuropharmacology. 2014 May;80:34-44. doi: 10.1016/j.neuropharm.2014.01.039. Epub 2014 Jan 31. Review.

PMID:
24486378
15.

Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease.

Schaeffer EL, Forlenza OV, Gattaz WF.

Psychopharmacology (Berl). 2009 Jan;202(1-3):37-51. doi: 10.1007/s00213-008-1351-0. Epub 2008 Oct 14. Review.

PMID:
18853146
16.

Is there any therapeutic value for the use of histone deacetylase inhibitors for chronic pain?

Wang W, Cui SS, Lu R, Zhang H.

Brain Res Bull. 2016 Jul;125:44-52. doi: 10.1016/j.brainresbull.2016.04.010. Epub 2016 Apr 22. Review.

PMID:
27090944
17.

The roles of class I histone deacetylases (HDACs) in memory, learning, and executive cognitive functions: A review.

Schmauss C.

Neurosci Biobehav Rev. 2017 Oct 7;83:63-71. doi: 10.1016/j.neubiorev.2017.10.004. [Epub ahead of print] Review.

PMID:
29017914
18.

CREB and the discovery of cognitive enhancers.

Scott R, Bourtchuladze R, Gossweiler S, Dubnau J, Tully T.

J Mol Neurosci. 2002 Aug-Oct;19(1-2):171-7. Review.

PMID:
12212777
19.

Epigenetic Treatment of Neurodegenerative Disorders: Alzheimer and Parkinson Diseases.

Irwin MH, Moos WH, Faller DV, Steliou K, Pinkert CA.

Drug Dev Res. 2016 May;77(3):109-23. doi: 10.1002/ddr.21294. Epub 2016 Feb 21. Review.

PMID:
26899010
20.

The aging memory: Modulating epigenetic modifications to improve cognitive function.

Fonseca R.

Neurobiol Learn Mem. 2016 Sep;133:182-184. doi: 10.1016/j.nlm.2016.07.002. Epub 2016 Jul 4. Review.

PMID:
27390098

Supplemental Content

Support Center